Patients with metastatic melanoma treated with high-dose interleukin-2 demonstrated improved OS compared with historical reference standards, according to study results presented at the HemOnc Today Melanoma and Cutaneous Malignancies meeting.
Conferences
T-VEC extends OS in patients with unresected stage III/IV melanoma
Patients with unresected stage IIIb, stage IIIc or stage IV melanoma treated with talimogene laherparepvec demonstrated a durable OS advantage compared with those who received granulocyte-macrophage colony–stimulating factor, according to study results presented at the HemOnc Today Melanoma and Cutaneous Malignancies meeting.
What you need to know about sunscreen (but were too afraid to ask)
World authority on sunscreen, Dr Curtis Cole, presented the facts and fiction about sunscreen at our recorded webinar hosted by Melanoma Institute Australia.
Dr Cole has spent 40 years developing and evaluating sunscreen products, and providing technical insight into sun protection, skin photobiology, skin ageing and general skin care. He is the former Vice President of Research and Development at Johnson & Johnson Consumer Products Skin Care.
Systemic therapy plays role in evolving paradigm for brain metastases
NEW YORK — Effective targeted therapies and immunotherapies for melanoma are likely to also be effective for the treatment of brain metastases, according to a presenter at the HemOnc Today Melanoma and Cutaneous Malignancies meeting.